Awawu Igbinadolor, MD
Internal medicine, Member of Royal College of
Physicians (MRCP), United Kingdom
During the Pandemic, Dr. Igbinadolor was one of the highest enrolling investigators on a study evaluating a groundbreaking mAB treatment for COVID-19. As a result of her contribution, she was a signatory on the findings submitted to the FDA for the COVID treatment’s Emergency Use Authorization.
She was also one of the top performing investigators on a phase I COVID treatment study, including the first and second in human dose of the landmark investigational treatment.